Assessing Unicycive Therapeutics (UNCY) Valuation As Q1 Loss Widens And FDA Decision On OLC Nears

Simply Wall St.05-16

AdvertisementWhy Unicycive Therapeutics (UNCY) is Back on Investors’ Radar Unicycive Therapeutics (UNCY) has drawn fresh attention after reporting its first quarter 2026 results, showing a net loss of...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2635647050?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-05-16 14:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2635647050","market":"sg","top_or_hot":-1,"title":"Assessing Unicycive Therapeutics (UNCY) Valuation As Q1 Loss Widens And FDA Decision On OLC Nears","media":"Simply Wall St.","content":"<div>\n<p>AdvertisementWhy Unicycive Therapeutics (UNCY) is Back on Investors’ Radar Unicycive Therapeutics (UNCY) has drawn fresh attention after reporting its first quarter 2026 results, showing a net loss of...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-uncy/unicycive-therapeutics/news/assessing-unicycive-therapeutics-uncy-valuation-as-q1-loss-w\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Assessing Unicycive Therapeutics (UNCY) Valuation As Q1 Loss Widens And FDA Decision On OLC Nears</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAssessing Unicycive Therapeutics (UNCY) Valuation As Q1 Loss Widens And FDA Decision On OLC Nears\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-05-16 14:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-uncy/unicycive-therapeutics/news/assessing-unicycive-therapeutics-uncy-valuation-as-q1-loss-w><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AdvertisementWhy Unicycive Therapeutics (UNCY) is Back on Investors’ Radar Unicycive Therapeutics (UNCY) has drawn fresh attention after reporting its first quarter 2026 results, showing a net loss of...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-uncy/unicycive-therapeutics/news/assessing-unicycive-therapeutics-uncy-valuation-as-q1-loss-w\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-uncy/unicycive-therapeutics/news/assessing-unicycive-therapeutics-uncy-valuation-as-q1-loss-w","article_id":"2635647050","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-uncy/unicycive-therapeutics/news/assessing-unicycive-therapeutics-uncy-valuation-as-q1-loss-w","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2635647050","pubTimestamp":1778913646,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Why Unicycive Therapeutics (UNCY) is Back on Investors’ Radar\nUnicycive Therapeutics (UNCY) has drawn fresh attention after reporting its first quarter 2026 results, showing a net loss of $12.82 million alongside ongoing FDA review of oxylanthanum carbonate with a June 29, 2026 PDUFA date.\nThis combination of a wider quarterly loss, preparations for a possible oxylanthanum carbonate launch, and a defined regulatory decision date is shaping how investors are reassessing the stock’s risk and...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","UNCY":"Unicycive Therapeutics, Inc.","BK4539":"次新股","BK4585":"ETF&股票定投概念","BK4139":"生物科技","LABU":"三倍做多标普生物-Direxion"},"translate_title":"随着第一季度亏损扩大以及FDA对OLC的决定临近，评估Unicycive Therapeutics(UNCY)的估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LABU":1.5,"UNCY":1.5},"content_text":"AdvertisementWhy Unicycive Therapeutics (UNCY) is Back on Investors’ Radar Unicycive Therapeutics (UNCY) has drawn fresh attention after reporting its first quarter 2026 results, showing a net loss of $12.82 million alongside ongoing FDA review of oxylanthanum carbonate with a June 29, 2026 PDUFA date. This combination of a wider quarterly loss, preparations for a possible oxylanthanum carbonate launch, and a defined regulatory decision date is shaping how investors are reassessing the stock’s risk and potential reward profile. See our latest analysis for Unicycive Therapeutics. UNCY’s share price has risen 18.51% over the past 30 days and 42.41% year to date, while the 3 year total shareholder return is down 40.14%. This suggests recent momentum is building after a weaker longer term experience as investors weigh the wider Q1 loss, recent equity issuance and the upcoming FDA decision. If you want to see what else is moving around key healthcare and biotech catalysts, this is a good moment to scan a focused list of 32 healthcare AI stocks. With the stock up 42.41% year to date and trading at a steep intrinsic discount, the key question now is simple: is Unicycive still mispriced, or is the market already baking in future growth? Most Popular Narrative: 61.6% Undervalued According to the most followed narrative, Unicycive’s fair value of $21.53 sits well above the recent $8.26 share price, which is why some investors are paying close attention to the current discount.  Unicycive can potentially be a US$500m drug in 2029. Take the analysis we used above of 450,000 patients where OLC gets 4% to 5% market share in the third year after launch, but where the drug is priced at only US$2,000 per month. This suggests a US$500m revenue level. We think the US$500m assumption is conservative and accounts for the post-2028 market environment that would see lower pricing pressure, but higher patient uptake given the clinical effectiveness.  Read the complete narrative. The heart of this narrative is a single product thesis, built around ambitious revenue ramp assumptions, hefty margins, and a premium earnings multiple that together underpin that $21.53 fair value. Result: Fair Value of $21.53 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, this hinges on successful FDA approval and execution of the OLC launch. Any regulatory setbacks or slower uptake are likely to challenge the undervaluation thesis. Find out about the key risks to this Unicycive Therapeutics narrative. Another View: Multiples Paint A Very Different Picture That $21.53 fair value hinges on optimistic cash flow assumptions, but the current P/B of 5.8x is far higher than both the peer average of 2.0x and the US biotech average of 2.4x. So is the stock attractively mispriced, or is the market already paying up for the story? To see how this valuation gap looks when you focus on one simple ratio, take a closer look at the See what the numbers say about this price — find out in our valuation breakdown. NasdaqCM:UNCY P/B Ratio as at May 2026Next Steps Given the mix of optimism and caution throughout this story, it makes sense to look at the full picture yourself and move quickly while the data is fresh. Start by weighing the 2 key rewards and 3 important warning signs. Looking for more investment ideas? If you are reassessing Unicycive today, it is a smart time to widen your watchlist and line up a few more candidates for closer research.  Target stability with companies that prioritise financial strength by scanning the solid balance sheet and fundamentals stocks screener (45 results). Hunt for value where price and quality still look out of sync by reviewing the 50 high quality undervalued stocks. Spot potential early movers by tracking focused opportunities in the 25 elite penny stocks with strong financials.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2635647050","isCrawlerRequest":true}